Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
Holding NRIX?
Track your performance easily
NRIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.22 - $26.31
Previous Close$24.74
Volume703.57K
Average Volume (3M)783.29K
Market Cap
$1.59B
Enterprise Value$1.18B
Total Cash (Recent Filing)$443.14M
Total Debt (Recent Filing)$28.82M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Oct 10, 2024EPS Estimate
-$0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.92
Shares Outstanding64,411,870
10 Day Avg. Volume471,094
30 Day Avg. Volume783,287
Standard Deviation0.24
R-Squared0.21
Alpha0.00201
Financial Highlights & Ratios
Price to Book (P/B)4.30
Price to Sales (P/S)25.67
Price to Cash Flow (P/CF)-10.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue18.93
Enterprise Value/Gross Profit15.32
Enterprise Value/Ebitda-7.60
Forecast
1Y Price Target
$29.27Price Target Upside16.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Nurix Therapeutics News
PremiumCompany Announcements
Nurix Therapeutics Showcases Breakthrough BTK Degraders
Bulls Say, Bears Say
Bulls Say
Analyst RatingAnalyst raises the probability of approval for NX-5948 to 50% from the prior 30%.
EfficacyNX-5948 elicited a 69.2% ORR in 26 evaluable CLL patients, a considerable improvement relative to the 42.9% ORR seen previously.
Safety ProfileNX-5948 demonstrated a tolerable safety profile and deepening responses with longer treatment duration and follow up.
Bears Say
Disease ProgressionA patient with primary central nervous system lymphoma experienced disease progression with a new brain lesion after initial complete response to NX-5948.
Drug ToleranceBGB-16673 appears to have a slightly less tolerable profile, as evidenced by dose reduction/interruption in 37% of patients.
Treatment DurabilityA new lesion had formed by Week 16, indicating combination therapy may be required for durability.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NRIX FAQ
What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $4.22 and its highest was $26.31 in the past 12 months.
What is Nurix Therapeutics’s market cap?
Currently, no data Available
When is Nurix Therapeutics’s upcoming earnings report date?
Nurix Therapeutics’s upcoming earnings report date is Oct 10, 2024 which is in 20 days.
How were Nurix Therapeutics’s earnings last quarter?
Nurix Therapeutics released its earnings results on Jul 11, 2024. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.635 by -$0.075.
Is Nurix Therapeutics overvalued?
According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued.
Does Nurix Therapeutics pay dividends?
Nurix Therapeutics does not currently pay dividends.
What is Nurix Therapeutics’s EPS estimate?
Nurix Therapeutics’s EPS estimate is -$0.67.
How many shares outstanding does Nurix Therapeutics have?
Nurix Therapeutics has 64,411,870 shares outstanding.
What happened to Nurix Therapeutics’s price movement after its last earnings report?
Nurix Therapeutics reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.635. Following the earnings report the stock price went up 8.125%.
Which hedge fund is a major shareholder of Nurix Therapeutics?
Among the largest hedge funds holding Nurix Therapeutics’s share is Baker Bros Advisors LP. It holds Nurix Therapeutics’s shares valued at 81M.
---
Nurix Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.27 (16.80% Upside)
$29.27 (16.80% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
177.66%
12-Months-Change
Fundamentals
Return on Equity
-52.33%
Trailing 12-Months
Asset Growth
45.75%
Trailing 12-Months
Company Description
Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
---
NRIX Stock 12 Month Forecast
Average Price Target
$29.27
▲(16.80% Upside)
Technical Analysis
Best Analysts Covering NRIX
1 Year
1 Year Success Rate
11/15 ratings generated profit
1 Year Average Return
+82.19%
reiterated a buy rating 2 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +82.19% per trade.
---